Report of Foreign Issuer (6-k)
August 03 2020 - 7:06AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of August 2020
Commission
File Number 001-15170
GlaxoSmithKline plc
(Translation
of registrant's name into English)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ____
Issued: 31st July
2020, London, UK and Paris, France
GlaxoSmithKline plc
Sanofi and GSK in advanced discussions with European Union to
supply up to 300 million doses of COVID-19 vaccine
●
Discussions relate
to vaccine candidate using Sanofi's recombinant protein-based
technology combined with GSK's pandemic adjuvant
system
●
Both
companies are committed to making their COVID-19 vaccine affordable
and available globally
Sanofi and GSK are in advanced discussions with the European
Commission (EC) for the supply of up to 300 million doses of a
COVID-19 vaccine. The vaccine candidate developed by Sanofi in
partnership with GSK, is based on the recombinant protein-based
technology used by Sanofi to produce an influenza vaccine, and
GSK's established adjuvant technology. The doses would be
manufactured in European countries including France, Belgium,
Germany and Italy. This marks a key milestone in protecting and
serving the European population against COVID-19.
"Today's announcement helps to ensure that millions of
Europeans will have access to a potential vaccine protecting
against COVID-19, once proven safe and effective. It has been our
steadfast commitment to provide a vaccine that is affordable and
accessible to everyone, and we are grateful to the European
Commission for their ongoing engagement and shared support of this
effort," said Thomas Triomphe, Executive Vice President and Global
Head of Sanofi Pasteur. "Together with GSK, we are working
relentlessly to develop and produce a vaccine to address this
global health crisis."
Roger Connor, President of GSK Vaccines added "GSK is proud to be
working in partnership with Sanofi to make this vaccine available
as soon as possible in Europe. Both companies have significant
R&D and manufacturing capability in Europe and are already
working hard to scale up production across our networks. This
announcement from the EC supports our ongoing
efforts."
Sanofi is leading the clinical development and registration of the
COVID-19 vaccine and expects a Phase 1/ 2 study to start in
September, followed by a Phase 3 study by the end of 2020. If data
are positive, regulatory approval could be achieved by the first
half of 2021. In parallel, Sanofi and GSK are scaling up
manufacturing of the antigen and adjuvant to produce up to one
billion doses per year overall.
Sanofi and GSK are committed to making the vaccine available
globally
Sanofi and GSK recently signed agreements with the United States
where they have a longstanding partnership with the Biomedical
Advanced Research and Development Authority, and also with the UK
Government. The partners plan to provide a significant
portion of total worldwide available supply capacity in 2021/22 to
the global initiative "Access to COVID‐19
Tools (ACT) Accelerator," a global collaboration of leaders of
governments, global health organizations, businesses and
philanthropies to accelerate development, production, and equitable
access to COVID-19 tests, treatments, and
vaccines.
GSK commitment to tackling COVID-19
GSK is collaborating with companies and research groups across the
world working on promising COVID-19 vaccine candidates through the
use of our innovative vaccine adjuvant technology. The use of an
adjuvant is of particular importance in a pandemic situation since
it may reduce the amount of vaccine protein required per dose,
allowing more vaccine doses to be produced and therefore
contributing to protecting more people. GSK does not expect
to profit from COVID-19 vaccines during the pandemic phase, and
will invest any short-term profit in coronavirus related research
and long-term pandemic preparedness, either through GSK internal
investments or with external partners.
About GSK
GSK is a science-led global healthcare company with a special
purpose: to help people do more, feel better, live longer. For
further information please visit www.gsk.com/about-us.
About Sanofi
Sanofi is dedicated to supporting people through their health
challenges. We are a global biopharmaceutical company focused on
human health. We prevent illness with vaccines, provide innovative
treatments to fight pain and ease suffering. We stand by the few
who suffer from rare diseases and the millions with long-term
chronic conditions.
With more than 100,000 people in 100 countries, Sanofi is
transforming scientific innovation into healthcare solutions around
the globe.
GSK enquiries:
|
|
|
|
Media
enquiries:
|
Simon
Steel
|
+44 (0)
20 8047 5502
|
(London)
|
|
Simon
Moore
|
+44 (0)
20 8047 5502
|
(London)
|
|
Kristen
Neese
|
+1 804
217 8147
|
(Philadelphia)
|
|
Kathleen
Quinn
|
+1 202
603 5003
|
(Washington
DC)
|
|
|
|
|
Analyst/Investor
enquiries:
|
Sarah
Elton-Farr
|
+44 (0)
20 8047 5194
|
(London)
|
|
Sonya
Ghobrial
|
+44 (0)
7392 784784
|
(Consumer)
|
|
Danielle
Smith
|
+44 (0)
20 8047 0932
|
(London)
|
|
James
Dodwell
|
+44 (0)
20 8047 2406
|
(London)
|
|
Jeff
McLaughlin
|
+1 215
751 7002
|
(Philadelphia)
|
|
Frannie
DeFranco
|
+1 215
751 4855
|
(Philadelphia)
|
Cautionary statement regarding forward-looking
statements
GSK cautions investors that any forward-looking statements or
projections made by GSK, including those made in this announcement,
are subject to risks and uncertainties that may cause actual
results to differ materially from those projected. Such factors
include, but are not limited to, those described under Item 3.D
"Risk Factors" in the company's Annual Report on Form 20-F for 2019
and as set out in GSK's Principal risks and uncertainties" section
of the Q2 Results and any impacts of the COVID-19
pandemic.
Registered in England & Wales:
No. 3888792
Registered Office:
980 Great West Road
Brentford, Middlesex
TW8 9GS
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
GlaxoSmithKline plc
|
|
(Registrant)
|
|
|
Date: August
3, 2020
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
Victoria Whyte
|
|
Authorised
Signatory for and on
|
|
behalf
of GlaxoSmithKline plc
|
GSK (NYSE:GSK)
Historical Stock Chart
From Aug 2024 to Sep 2024
GSK (NYSE:GSK)
Historical Stock Chart
From Sep 2023 to Sep 2024